Patent ID: 11867701
Assignee: WASHINGTON UNIVERSITY
Field: Measurement (Instruments)
Classification: CPC G  C  A | IPC C  G

Claim 0:
1. A method of determining treatment of a subject with Crohn's disease, the method comprising:
a) detecting human defensin 5 (HD5) protein by immunostaining of HD5 in a biological sample obtained from the subject;
b) identifying the number of HD5 positive cells in the biological sample with normal or abnormal HD5 localization and/or distribution, wherein abnormal includes disordered, diminished, diffuse, excluded and enlarged granule morphology;
c) classifying the subject as having
i) a Type II phenotype if <20% of cells have abnormal HD5 localization and/or distribution, or
ii) a Type I phenotype if ≥20% of cells have abnormal HD5 localization and/or distribution and

d) administering 5-aminosalicylate, corticosteroid, azathioprine, mercaptopurine, infliximab, adalimumab, certolizumab pegol, methotrexate, cyclosporine, tacrolimus, Natalizumab, vedolizumab, ustekinumab, antibiotics, anti-diarrheals, pain relievers, iron supplements, vitamin B-12 shots, calcium supplement, vitamin D supplement, or surgical procedure to the subject classified as Type II, or administering surgical procedure and one or more of 5-am inosalicylate, corticosteroid, azathioprine, mercaptopurine, infliximab, adalimumab, certolizumab pegol, methotrexate, cyclosporine, tacrolimus, Natalizumab, vedolizumab, ustekinumab, antibiotics, anti-diarrheals, pain relievers, iron supplements, vitamin B-12 shots, calcium supplement, and vitamin D supplement to the subject classified as Type I based on the classification of the subject as determined in step c).